Sutro Biopharma Q2 FY26 net loss widens to USD 38.53 million; revenue drops to USD 9.84 million - STRO News | RalliesSutro Biopharma Q2 FY26 net loss widens to USD 38.53 million; revenue drops to USD 9.84 million
S
STRO• Pipeline update
- STRO-004 Phase 1 showed early partial responses with low AE-driven discontinuations; STRO-006 trial start targeted for Q3 2026.
Q2 results and cash position
- Sutro Biopharma Q2 revenue fell 84.56% to USD 9.84 million.
- Net loss widened to USD 38.53 million, or USD 2.33 per share.
- Operating loss widened to USD 29.89 million; total operating expenses dropped 40.8% to USD 39.73 million.
- Cash, cash equivalents and marketable securities totaled USD 164.35 million at June 30, supporting operations into at least Q2 2028.
KGC
•
